Screener
Allogene Therapeutics ALLO Total Revenue
Discontinued — last reported Q4 '25
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Allogene Therapeutics’s 10-K, filed March 12, 2026.
- Filed
- Mar 12, 2026, 4:11 PM EDT
- Fiscal year
- FY2025
- Accession
- 0001628280-26-017242
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Collaboration revenue - related party | — | $22 |
| Operating expenses: | ||
| Research and development | 150,152 | 192,299 |
| General and administrative | 56,781 | 65,205 |
| Impairment of long-lived asset | 2,382 | 15,717 |
| Total operating expenses | 209,315 | 273,221 |
| Loss from operations | (209,315) | (273,199) |
| Other income (expense), net: |
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Allogene Therapeutics's total revenue?
- Allogene Therapeutics (ALLO) reported total revenue of $0 in Q4 2025.
- What is the long-term trend for Allogene Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Allogene Therapeutics's total revenue has grown at a -100.0% compound annual growth rate (CAGR), from $114.09M to $0.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Allogene Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude